





Immunology

Antibodies for Immunology Research





bxcell.com




Antibodies for Immunology Research





| Antigen | Reactivity | Application | Clone | InVivoMab Catalog | InVivoPlus Catalog |
|----------------------------------|-----------------|--|---------------------------------------|-------------------|--------------------|
| 2C TCR | mouse | IF, FC | 1B2 | BE0069 | |
| 4-1BB (CD137) | mouse | <i>in vivo</i> activation of 4-1BB | LOB12.3 | BE0169 | BP0169 |
| 4-1BB (CD137) | mouse | <i>in vivo</i> and <i>in vitro</i> 4-1BB stimulation | 3H3 | BE0239 | BP0239 |
| 4-1BB (CD137) | mouse | <i>in vitro</i> 4-1BB blockade, FC | 17B5 | BE0296 | |
| 4-1BBL (CD137L) | mouse | <i>in vivo</i> 4-1BBL blockade | TKS-1 | BE0110 | |
| B220 | mouse | <i>in vivo</i> B cell depletion, <i>in vitro</i> B cell negative selection | RA3.3A1/6.1 | BE0067 | |
| B7-1 (CD80) | mouse | <i>in vivo</i> B7-1 blockade, Affinity chromatography | 1G10 | BE0134 | |
| BTLA (CD272) | mouse | <i>in vivo</i> BTLA stimulation, <i>in vivo</i> BTLA blockade | 6A6 | BE0132 | |
| BTLA (CD272) | mouse | <i>in vivo</i> and <i>in vitro</i> stimulation of BTLA, FC | PK18.6 | BE0153 | |
| BTLA (CD272) | mouse | <i>in vivo</i> BTLA blockade, <i>in vitro</i> T cell stimulation/activation, FC | PJ196 | BE0196 | |
| BTLA (CD272) | mouse | <i>in vivo</i> BTLA+ B cell and CD4 T cell depletion, FC | 6F7 | BE0304 | |
| c-Kit (CD117) | mouse | FC, IF, IHC | 2B8 | BE0280 | |
| c-Kit (CD117) | mouse | <i>in vivo</i> mast cell depletion, <i>in vivo</i> c-Kit+ cell depletion, <i>in vitro</i> c-Kit neutralization, IP, FC | ACK2 | BE0293 | |
| CCL2 (MCP-1) | mouse/human/rat | <i>in vivo</i> CCL2 neutralization, IHC-F | 2H5 | BE0185 | |
| CCR3 (CD193) | mouse | <i>in vivo</i> eosinophil depletion | 6S2-19-4 | BE0316 | |
| CD1a | human | <i>in vitro</i> CD1a blockade, FC | OKT-6 | BE0211 | |
| CD1d (CD1.1) | mouse | <i>in vivo</i> CD1d neutralization | 19G11 | BE0000 | |
| CD1d (CD1.1) | mouse | <i>in vivo</i> CD1d blockade, iNKT cell neutralization, FC | 20H2 (HB323) | BE0179 | |
| CD3 | human | <i>in vivo</i> T cell depletion in humanized mice, <i>in vitro</i> T cell stimulation/activation, ex vivo T cell inhibition for xenographs, FC | OKT-3 | BE0001-2 | |
| CD3 | mouse | <i>in vitro</i> T cell stimulation/activation | 17A2 | BE0002 | |
| CD3 | human | <i>in vivo</i> T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, FC | UCHT1 (Leu-4) (T3) | BE0231 | |
| CD3ε | mouse | <i>in vivo</i> T cell depletion, <i>in vitro</i> T cell stimulation/activation, IF, FC | 145-2C11 | BE0001-1 | BP0001-1 |
| CD3ε | mouse | <i>in vitro</i> T cell negative selection, <i>in vitro</i> T cell stimulation/activation, IF | KT3 | BE0261 | |
| CD3ε F(ab) ₂ fragment | mouse | <i>in vivo</i> T cell depletion | 145-2C11 f(ab) ₂ Fragments | BE0001-1FAB | |
| CD4 | mouse | <i>in vivo</i> CD4+ T cell depletion, FC | GK1.5 | BE0003-1 | BP0003-1 |
| CD4 | human | <i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD4+ T cell depletion in humanized mice, FC, IP | OKT-4 | BE0003-2 | |
| CD4 | mouse | <i>in vivo</i> blockade of CD4+ T-cell responses, WB | YTS 177 | BE0003-3 | |
| CD4 | mouse | <i>in vivo</i> CD4+ T cell depletion | YTS 191 | BE0119 | |
| CD4 | human | <i>in vitro</i> CD4 blockade, <i>in vitro</i> blocking of CD4+ T cell activation, IF, IHC-F, FC | RPA-T4 | BE0288 | |
| CD4 | rat | <i>in vivo</i> CD4+ T cell depletion, FC | OX-38 | BE0308 | |
| CD8 (Lyt 2.1) | mouse | <i>in vivo</i> CD8+ T cell depletion, FC | 116-13.1 (HB129) | BE0118 | |
| CD8α | mouse | <i>in vivo</i> CD8+ T cell depletion, IF, FC | 53-6.7 | BE0004-1 | BP0004-1 |
| CD8α | human | <i>in vivo</i> CD8+ T cell depletion in humanized mice | OKT-8 | BE0004-2 | |
| CD8α | mouse | <i>in vivo</i> CD8+ T cell depletion | 2.43 | BE0061 | BP0061 |
| CD8α | mouse | <i>in vivo</i> CD8+ T cell depletion | YTS 169.4 | BE0117 | |
| CD8β (Lyt 3.2) | mouse | <i>in vivo</i> CD8+ T cell depletion, <i>in vitro</i> CD8 blockade, IF | 53-5.8 | BE0223 | |
| CD11b | mouse/human | <i>in vivo</i> CD11b neutralization, ILC2 cell purification, FC | M1/70 | BE0007 | |
| CD16/CD32 | mouse | <i>in vitro</i> and <i>in vivo</i> Fc receptor blocking | 2.4G2 | BE0307 | |
| CD19 | mouse | <i>in vivo</i> B cell depletion, <i>in vivo</i> CD19 neutralization, <i>in vitro</i> B cell negative selection, FC | 1D3 | BE0150 | |
| CD19 | human | Functional assays, Chimeric antigen receptor construction, FC, IF | 4G7 | BE0281 | |
| CD22 | mouse | <i>in vivo</i> B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat Light Chain (clone MAR 18.5), FC, IP | Cy34.1 | BE0011 | |
| CD25 (IL-2Rα) | mouse | <i>in vivo</i> regulatory T cell depletion, FC | PC-61.5.3 | BE0012 | BP0012 |
| CD25 (IL-2Rα) | human | IP, IF | 7G7B6 | BE0014 | |
| CD28 | mouse | <i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD28 blockade | 37.51 | BE0015-1 | |
| CD28 | mouse | <i>in vitro</i> T cell stimulation/activation | PV-1 | BE0015-5 | |
| CD28 | mouse | <i>in vivo</i> and <i>in vitro</i> T cell stimulation/activation | D665 | BE0328 | |
| CD32 (FcγRIIA) | human | <i>in vivo</i> FcγRIIA blockade in humanized mice, <i>in vitro</i> FcγRIIA blockade, ELISA, FC | IV.3 | BE0224 | |
| CD38 | mouse | <i>in vivo</i> and <i>in vitro</i> CD38 stimulation, <i>in vitro</i> B cell activation, IF | NIMR5 | BE0317 | |
| CD40 | mouse | <i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation | FGK4.5/FGK45 | BE0016-2 | BP0016-2 |
| CD40 | human | <i>in vitro</i> B cell stimulation, <i>in vitro</i> macrophage stimulation, Functional assays, FC | G28.5 | BE0189 | |
| CD40L (CD154) | mouse | <i>in vivo</i> and <i>in vitro</i> blocking of CD40/CD40L signaling | MR-1 | BE0017-1 | BP0017-1 |
| CD40L (CD154) | human/monkey | <i>in vivo</i> and <i>in vitro</i> blocking of CD40/CD40L signaling, IP, FC | 5C8 | BE0292 | |



| Antigen | Reactivity | Application | Clone | InVivoMab Catalog | InVivoPlus Catalog |
|-------------------------------|-----------------|---|----------------|-------------------|--------------------|
| CD45RB | mouse | <i>in vivo</i> anti-CD45RB-mediated tolerance induction, <i>in vivo</i> pre-mNK cell depletion | MB23G2 (HB220) | BE0019 | |
| CD45.2 | mouse | FC, IHC-F, <i>in vitro</i> CD45.2 blockade, <i>in vivo</i> CD45.2 blockade | 104.2 | BE0300 | |
| CD47 | human | <i>in vivo</i> CD47 neutralization in human tumor xenograft models or humanized mice, <i>in vitro</i> CD47 neutralization, FC | B6H12 | BE0019-1 | |
| CD47 | human/mouse/rat | <i>in vivo</i> and <i>in vitro</i> CD47 blockade, IF | MIAP410 | BE0283 | BP0283 |
| CD47 (IAP) | mouse | <i>in vivo</i> CD47 blockade, IF | MIAP301 | BE0270 | |
| CD48 | mouse | <i>in vivo</i> and <i>in vitro</i> CD48 blockade | HM48-1 | BE0147 | |
| CD54 (ICAM-1) | mouse | <i>in vivo</i> ICAM-1 neutralization | YN1/1.7.4 | BE0020-1 | |
| CD69 | mouse | <i>in vivo</i> down-regulation of CD69 expression, Functional assays | CD69.2.2 | BE0330 | |
| CD70 | mouse | <i>in vivo</i> and <i>in vitro</i> CD70 blockade, FC | FR70 | BE0022 | |
| CD71 (TfR1) | mouse | <i>in vivo</i> depletion of CD71+ cells, IF, IHC-F, WB | 8D3 | BE0329 | |
| CD71 (TfR1) | rat/mouse | Targeted drug delivery to the brain, IHC-F, FC | OX-26 | BE0331 | |
| CD73 | mouse | <i>in vivo</i> CD73 blockade | TY/23 | BE0209 | |
| CD80 | rat | FC | 3H5 | BE0187 | |
| CD80 (B7-1) | mouse | <i>in vivo</i> CD80 blockade, FC | 16-10A1 | BE0024 | |
| CD86 (B7-2) | mouse | <i>in vivo</i> CD86 blockade, FC | GL-1 | BE0025 | |
| CD96 | mouse | <i>in vivo</i> and <i>in vitro</i> CD96 blocking, FC | 3.3 | BE0337 | |
| CD103 | mouse | <i>in vivo</i> CD103 neutralization, IF, FC | M290 | BE0026 | |
| CD106 (VCAM-1) | mouse | <i>in vivo</i> VCAM-1 neutralization, IF | M/K-2.7 | BE0027 | |
| CD122 (IL-2R β) | mouse | <i>in vitro</i> NK cell negative selection, IP, FC | 5H4 | BE0272 | |
| CD122 (IL-2R β) | mouse | <i>in vivo</i> NK cell depletion, <i>in vitro</i> IL-2R blockade, Functional assays, FC | TM-Beta 1 | BE0298 | |
| CD132 (common γ chain) | mouse | <i>in vivo</i> γ c blockade, Functional assays, IP, FC | 3E12 | BE0271 | |
| CD172a (SIRP α) | mouse | <i>in vivo</i> and <i>in vitro</i> SIRP α blocking, WB, IP, FC | P84 | BE0322 | |
| CD200 (OX2) | mouse | <i>in vivo</i> and <i>in vitro</i> CD200 blockade, IHC-F, IF, FC | OX-90 | BE0299 | |
| CD209b (SIGN-R1) | mouse | <i>in vivo</i> SIGN-R1 blockade, IHC-F, WB, FC | 22D1 | BE0220 | |
| CD276 (B7-H3) | mouse | <i>in vivo</i> B7-H3 blockade, FC | MJ18 | BE0124 | |
| CD314 (NKG2D) | mouse | <i>in vivo</i> and <i>in vitro</i> NKG2D blockade, FC | CX5 | BE0334 | |
| CD317 (BST2, PDCA-1) | mouse | <i>in vivo</i> pDC depletion, IF, FC | 927 | BE0311 | |
| CLEC9A (CD370) | mouse | <i>in vivo</i> Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC | 7H11 | BE0305 | |
| CSF1 | mouse | <i>in vitro</i> CSF1 neutralization | 5A1 | BE0204 | |
| CSF1R (CD115) | mouse | <i>in vivo</i> macrophage depletion, <i>in vivo</i> monocyte depletion, <i>in vitro</i> CSF-R1 neutralization, FC | AFS98 | BE0213 | BP0213 |
| CTLA-4 (CD152) | mouse | <i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization, FC | UC10-4F10-11 | BE0032 | BP0032 |
| CTLA-4 (CD152) | mouse | <i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization | 9H10 | BE0131 | BP0131 |
| CTLA-4 (CD152) | mouse | <i>in vivo</i> CTLA-4 neutralization | 9D9 | BE0164 | BP0164 |
| CTLA-4 (CD152) | human | <i>in vitro</i> CTLA-4 neutralization, FC | BN13 | BE0190 | |
| CXCL9 (MIG) | mouse | IF | MIG-2F5.5 | BE0309 | |
| CXCR3 (CD183) | mouse | <i>in vivo</i> CXCR3 neutralization, FC | CXCR3-173 | BE0249 | |
| Delta-like protein 4 (DLL4) | mouse | <i>in vivo</i> DLL4 neutralization | HMD4-2 | BE0127 | |
| DR5 (CD262) | mouse | <i>in vivo</i> induction TRAIL-mediated apoptosis, <i>in vitro</i> induction TRAIL-mediated apoptosis | MD5-1 | BE0161 | |
| F4/80 | mouse | <i>in vivo</i> Monocyte/Macrophage depletion, Functional assays, IHC-P, IHC-F, FC | Cl:A3-1 | BE0206 | |
| FasL (CD178) | mouse | <i>in vivo</i> and <i>in vitro</i> FasL blockade, Functional assay, IHC-P, FC | MFL3 | BE0319 | |
| FGL-1 | mouse | <i>in vivo</i> and <i>in vitro</i> FGL-1 blockade, FC, IHC-P | 177R4 | BE0332 | |
| Galectin-9 | mouse | <i>in vivo</i> and <i>in vitro</i> Galectin-9 blockade | RG9-1 | BE0218 | |
| GITR | mouse | <i>in vivo</i> GITR stimulation | DTA-1 | BE0063 | BP0063 |
| GM-CSF | mouse | <i>in vivo</i> and <i>in vitro</i> GM-CSF neutralization, FC | MPI-22E9 | BE0259 | |
| ICOS | mouse | <i>in vivo</i> blocking of ICOS/ICOSL signaling, FC | 7E.17G9 | BE0059 | |
| ICOSL (CD275) | mouse | <i>in vivo</i> ICOSL neutralization | HK5.3 | BE0028 | |
| IFNAR-1 | mouse | <i>in vivo</i> and <i>in vitro</i> IFNAR-1 blockade | MAR1-5A3 | BE0241 | BP0241 |
| IFN γ | mouse | <i>in vivo</i> and <i>in vitro</i> IFN γ neutralization | R4-6A2 | BE0054 | |
| IFN γ | mouse | <i>in vivo</i> and <i>in vitro</i> IFN γ neutralization, ELISPOT, FC | XMG1.2 | BE0055 | BP0055 |
| IFN γ | human | <i>in vitro</i> IFN γ neutralization | B133.5 | BE0235 | |
| IFN γ | human | FC | B27 | BE0245 | |
| IFN γ | mouse | <i>in vivo</i> and <i>in vitro</i> IFN γ neutralization | H22 | BE0312 | |



| Antigen | Reactivity | Application | Clone | InVivoMab Catalog | InVivoPlus Catalog |
|---------------------------------------|--------------|--|-----------------|-------------------|--------------------|
| IFNγR (CD119) | mouse | <i>in vivo</i> IFNγR neutralization | GR-20 | BE0029 | |
| IFNγRα (CD119) | mouse | WB, IP, FC | 2E2 | BE0287 | |
| IL-1 R (CD121a) | mouse | <i>in vitro</i> IL-1 R blockade | JAMA-147 | BE0256 | |
| IL-10 | mouse | <i>in vivo</i> IL-10 neutralization, <i>in vitro</i> IL-10 neutralization | JES5-2A5 | BE0049 | |
| IL-10R (CD210) | mouse | <i>in vivo</i> blocking of IL-10/IL-10R signaling, <i>in vitro</i> blocking of IL-10R signaling, FC | 1B1.3A | BE0050 | BP0050 |
| IL-12 | mouse | <i>in vitro</i> IL-12 neutralization | R1-5D9 | BE0052 | |
| IL-12 p40 | mouse | <i>in vivo</i> IL-12p40 neutralization, p40 affinity chromatography, IP, ELISA, FC, WB | C17.8 | BE0051 | BP0051 |
| IL-12 p70 | human | Functional assays, ELISA, FC | 20C2 | BE0234 | |
| IL-12 p75 | mouse | <i>in vivo</i> IL-12p75 neutralization, ELISA | R2-9A5 | BE0233 | |
| IL-15 | mouse | <i>in vivo</i> and <i>in vitro</i> IL-15 neutralization | AIO.3 | BE0315 | |
| IL-17A | mouse | <i>in vivo</i> IL-17A neutralization | 17F3 | BE0173 | BP0173 |
| IL-17F | mouse | <i>in vivo</i> IL-17F neutralization | MM17F8F5.1A9 | BE0303 | |
| IL-18 | mouse | <i>in vivo</i> IL-18 neutralization | YIGIF74-1G7 | BE0237 | |
| IL-1α | mouse | <i>in vivo</i> IL-1α neutralization | ALF-161 | BE0243 | |
| IL-1β | mouse/rat | <i>in vivo</i> and <i>in vitro</i> IL-1β neutralization, ELISA | B122 | BE0246 | |
| IL-2 | mouse | <i>in vivo</i> and <i>in vitro</i> IL-2 neutralization, <i>in vivo</i> IL-2 receptor stimulation (as a complex with IL-2), ELISPOT, FC | JES6-5H4 | BE0042 | |
| IL-2 | mouse | <i>in vivo</i> IL-2 neutralization, <i>in vivo</i> IL-2 receptor stimulation (as a complex with IL-2) | JES6-1A12 | BE0043 | |
| IL-2 | mouse | <i>in vivo</i> IL-2 neutralization, <i>in vivo</i> IL-2 receptor stimulation (as a complex with IL-2) | S4B6-1 | BE0043-1 | |
| IL-21R | mouse | <i>in vivo</i> IL-21R blockade | 4A9 | BE0258 | |
| IL-23 (p19) | mouse | <i>in vivo</i> IL-23C1843p19 neutralization; WB | G23-8 | BE0313 | |
| IL-27 p28 | mouse | <i>in vivo</i> and <i>in vitro</i> IL-27 p28 neutralization, FC | MM27.7B1 | BE0326 | |
| IL-3 | mouse | <i>in vivo</i> and <i>in vitro</i> IL-3 neutralization, <i>in vivo</i> IL-3 receptor stimulation (as a complex with IL-3), ELISA, FC | MP2-8F8 | BE0282 | |
| IL-4 | mouse | <i>in vitro</i> and <i>in vivo</i> IL-4 neutralization, <i>in vivo</i> IL-4 receptor stimulation (as a complex with IL-4), FC | 11B11 | BE0045 | BP0045 |
| IL-4 | mouse | ELISA, ELISPOT, FC | BVD6-24G2 | BE0199 | |
| IL-4 | human | <i>in vitro</i> IL-4 neutralization, FC | MP4-25D2 | BE0240 | |
| IL-5 | mouse/human | <i>in vivo</i> IL-5 neutralization, <i>in vivo</i> eosinophil depletion | TRFK5 | BE0198 | |
| IL-6 | mouse | <i>in vivo</i> IL-6 neutralization, <i>in vitro</i> IL-6 neutralization | MP5-20F3 | BE0046 | |
| IL-6R | mouse | <i>in vivo</i> blocking of IL-6/IL-6R signaling, <i>in vitro</i> blocking of IL-6R signaling | 15A7 | BE0047 | |
| IL-7 | mouse/human | <i>in vivo</i> IL-7 neutralization, <i>in vivo</i> IL-7 receptor stimulation (as a complex with IL-7) | M25 | BE0048 | |
| IL-7Rα (CD127) | mouse | <i>in vivo</i> blocking of IL-7Rα signaling, FC | A7R34 | BE0065 | |
| IL-9 | mouse | <i>in vivo</i> IL-9 neutralization | 9C1 | BE0181 | |
| IL-9 | human | FC, ELISA | MH9A4 | BE0327 | |
| Jagged2 | mouse | <i>in vivo</i> Jagged 2 neutralization | HMJ2-1 | BE0125 | |
| Kappa Immunoglobulin Light Chain | rat | <i>in vivo</i> administration, FC | MAR 18.5 | BE0122 | |
| Kappa Immunoglobulin Light Chain | mouse | IF | 187.1 (HB58) | BE0176 | |
| KLRG-1 | mouse/human | FC | 2F1 | BE0201 | |
| LAG-3 | mouse | <i>in vivo</i> and <i>in vitro</i> LAG-3 neutralization, FC | C9B7W | BE0174 | BP0174 |
| Ly6C | mouse | <i>in vivo</i> macrophage depletion (in combination with clodronate liposomes), FC | Monts 1 | BE0203 | |
| Ly6G | mouse | <i>in vivo</i> neutrophil depletion, <i>in vivo</i> MDSC depletion, IF, IHC-P, IHC-F, FC | 1A8 | BE0075-1 | BP0075-1 |
| Ly6G/Ly6C (Gr-1) | mouse | <i>in vivo</i> neutrophil depletion, IHC-P, IHC-F, IF, FC | NIMP-R14 | BE0320 | |
| Ly6G/Ly6C (Gr-1) | mouse | <i>in vivo</i> depletion of Gr-1+ myeloid cells, FC, IHC-P, IHC-F | RB6-8C5 | BE0075 | BP0075 |
| MDR-1 (CD243) | human/monkey | <i>in vivo</i> MDR-1 blocking/depletion in xenogeneic murine tumor models, <i>in vitro</i> MDR-1 blocking, IHC-P | UIC2 | BE0340 | |
| MHC Class I (H-2) | mouse | <i>ex vivo</i> blocking of MHC I-dependent interactions, IF, FC | M1/42.3.9.8 | BE0077 | |
| MHC Class I (H-2Kb) | mouse | <i>in vivo</i> administration, FC | AF6-88.5.5.3 | BE0121 | |
| MHC Class I (H-2Kb) | mouse | Functional assays, Purification of MHC peptide complexes, FC | Y-3 | BE0172 | |
| MHC Class I (H-2Kb) bound to SIINFEKL | mouse | Functional assays, FC | 25-D1.16 | BE0207 | |
| MHC Class I (H-2Kd, H-2Dd) | mouse | <i>in vivo</i> activation of APCs | 34-1-2S | BE0180 | |
| MHC Class I (H-2Kd) | mouse | Purification of MHC peptide complexes, FC | SF1.110 (HB159) | BE0104 | |
| MHC Class I (H-2Kk, H-2Dk) | mouse | <i>in vivo</i> administration, FC | 15-3-1S (HB13) | BE0158 | |
| MHC Class I (H-2Kk, H-2Dk) | mouse | Functional assays, FC | 16-1-2N (HB14) | BE0228 | |
| MHC Class I (H-2Kk) | mouse | <i>in vivo</i> administration | AF3-12.1.3 | BE0152 | |
| MHC Class I (HLA-A, HLA-B, HLA-C) | human | Functional assays | W6/32 | BE0079 | |



| InVivoMab vs. InVivoPlus | | |
|---------------------------------------|--------------------|---------------------|
| | InVivoMab > 95% | InVivoPlus > 95% |
| purity level | > 95% | > 95% |
| protein aggregates validated at ≤5% | ✓ | ✓ |
| azide and carrier protein free | ✓ | ✓ |
| endotoxin concentration | < 2EU/mg | < 1EU/mg |
| validated by immunoblot, FC, or ELISA | ✓ | ✓ |
| tested for murine pathogens | ✓ | ✓ |
| available in bulk quantities | ✓ | ✓ |

| Antigen | Reactivity | Application | Clone | InVivoMab Catalog | InVivoPlus Catalog |
|---|--|---|-----------------|----------------------|-----------------------|
| MHC class II (HLA-DR) | human/monkey | <i>in vitro</i> blocking of MHC class II HLA-DR, HLA class II binding assay, <i>in vitro</i> MHC class II HLA-DR expressing cell negative selection, WB, FC | L243 | BE0306 | |
| MHC class II (I-A) | mouse | <i>in vivo</i> blockade of TCR stimulation, FC | Y-3P | BE0178 | |
| MHC Class II (I-A/I-E) | mouse | <i>in vivo</i> MHC II blockade, Functional assays, FC | M5/114 | BE0108 | |
| MHC II (I-Ak, I-Ar, I-Af, I-As, I-Ag7) | mouse | <i>in vitro</i> MHC class II I-A blocking, <i>in vitro</i> MHC class II I-A expressing cell negative selection | 10-3.6.2 | BE0068 | |
| MHC Class II (I-Ek/RT1-D) | mouse/rat | <i>in vivo</i> blocking of antigen presentation, FC | 14-4-4S (HB32) | BE0167 | |
| MHC Class II (β chain) | mouse | WB | KL277 | BE0140 | |
| NK1.1 | mouse | <i>in vivo</i> NK cell depletion, FC | PK136 | BE0036 | BP0036 |
| NKG2A/C/E | mouse | <i>in vivo</i> and <i>in vitro</i> NKG2A blockade, IHC-F, FC | 20D5 | BE0321 | |
| NKG2AB6 | mouse | FC | 16A11 | BE0339 | |
| NKG2D | mouse | <i>in vivo</i> NKG2D blockade | HMG2D | BE0111 | |
| Nonclassical MHC Class I molecule Qa-1b | mouse | WB, IF | 4C2.4A7.5H11 | BE0165 | |
| Notch4 | mouse | <i>in vitro</i> Notch4 stimulation, FC | HMN4-14 | BE0129 | |
| OX40 (CD134) | mouse | <i>in vivo</i> and <i>in vitro</i> OX40 activation | OX-86 | BE0031 | BP0031 |
| OX40L (CD134L) | mouse | <i>in vivo</i> blocking of OX40/OX40L signaling, <i>in vitro</i> OX40L neutralization | RM134L | BE0033-1 | |
| PD-1 (CD279) | mouse | <i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization | J43 | BE0033-2 | BP0033-2 |
| PD-1 (CD279) | mouse | <i>in vivo</i> blocking of PD-1/PD-L signaling | RMP1-14 | BE0146 | BP0146 |
| PD-1 (CD279) | human | <i>in vitro</i> PD-1 neutralization, <i>in vivo</i> PD-1 blockade in humanized mice | J116 | BE0188 | |
| PD-1 (CD279) | human | FC | J110 | BE0193 | |
| PD-1 (CD279) | mouse | <i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, FC, WB | 29F.1A12 | BE0273 | BP0273 |
| PD-L1 (B7-H1) | mouse | <i>in vivo</i> PD-L1 blockade, IF, IHC-F, FC | 10F.9G2 | BE0101 | BP0101 |
| PD-L1 (B7-H1) | human | <i>in vitro</i> PD-L1 blockade, Functional assays, IHC-F, FC | 29E.2A3 | BE0285 | |
| PD-L2 (B7-DC) | mouse | <i>in vivo</i> PD-L2 blockade, <i>in vitro</i> PD-L2 blockade, IHC-F, FC | TY25 | BE0112 | |
| PSGL-1 (CD162) | mouse | <i>in vivo</i> PSGL-1 blockade, IHC-F | 4RA10 | BE0186 | |
| RANKL (CD254) | mouse | <i>in vivo</i> RANKL blockade | IK22/5 | BE0191 | |
| Siglec-H | mouse | <i>in vivo</i> administration, FC | 440c | BE0202 | |
| TCR Vγ1.1/Cr4 | mouse | FC | 2.11 | BE0257 | |
| TCR γ/δ | mouse | <i>in vivo</i> TCR γ/δ neutralization, <i>in vitro</i> γ/δ T cell stimulation, <i>in vitro</i> γ/δ T cell purification, Functional assays, IP, FC | UC7-13D5 | BE0070 | |
| TCRβ | mouse | <i>in vivo</i> T cell depletion | H57-597 (HB218) | BE0102 | |
| Ter-119 | mouse | <i>in vivo</i> administration, Functional assays, FC | TER-119 | BE0183 | |
| TGF-β | mouse/human/rat/monkey/hamster/canine/bovine | <i>in vivo</i> and <i>in vitro</i> TGF-β neutralization | 1D11.16.8 | BE0057 | BP0057 |
| Thy1 (CD90) | mouse | <i>in vitro</i> T cell depletion | M5/49.4.1 | BE0076 | |
| Thy1.1 (CD90.1) | mouse | <i>in vivo</i> T cell depletion | 19E12 | BE0214 | |
| Thy1.2 (CD90.2) | mouse | <i>in vivo</i> ILC depletion, <i>in vivo</i> T cell depletion | 30H12 | BE0066 | BP0066 |
| TIGIT | mouse | <i>in vivo</i> TIGIT stimulation, FC | 1G9 | BE0274 | |
| TIM-1 (CD365) | mouse | <i>in vivo</i> TIM-1 neutralization | RMT1-10 | BE0113 | |
| TIM-1 (CD365) | mouse | <i>in vivo</i> TIM-1 activation, <i>in vitro</i> T cell stimulation/activation, Functional assays, ELISA, FC | 3B3 | BE0289 | |
| TIM-1 (CD365) | mouse | <i>in vivo</i> and <i>in vitro</i> TIM-1 blockade | 3D10 | BE0314 | |
| TIM-2 | mouse | | RMT2-29 | BE0114 | |
| TIM-3 (CD366) | mouse | <i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC | RMT3-23 | BE0115 | BP0115 |
| TIM-3 (CD366) | mouse | <i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC | B8.2C12 | BE0275 | |
| TIM-4 | mouse | <i>in vivo</i> and <i>in vitro</i> TIM-4 blockade, IF | RMT4-53 | BE0171 | |
| TIM-4 | mouse | <i>in vitro</i> TIM-4 blocking, IF, FC | RMT 4-54 | BE0225 | |
| TIM-4 | mouse | FC | F31-5G3 | BE0344 | |
| TL1A (TNFSF15) | mouse | <i>in vivo</i> TL1A neutralization, FC | 5G4.2 | BE0323 | |
| TNFR2 (CD120b) | mouse | <i>in vivo</i> and <i>in vitro</i> TNFR2 blockade | TR75-54.7 | BE0247 | |
| TNFα | mouse | <i>in vivo</i> and <i>in vitro</i> TNFα neutralization | XT3.11 | BE0058 | BP0058 |
| TNFα | mouse/rat/rabbit | <i>in vivo</i> TNFα neutralization, FC | TN3-19.12 | BE0244 | |
| VISTA | mouse | <i>in vivo</i> and <i>in vitro</i> blocking of VISTA signaling, FC | 13F3 | BE0310 | BP0310 |
| VLDL-R | mouse/rat/bovine | WB | IgG-6A6 | BE0345 | |
| Vβ4 TCR | mouse | <i>in vivo</i> administration, FC | KT4 | BE0166 | |
| Vβ8 TCR | mouse | FC | F23.1 | BE0182 | |
| Vγ2 TCR | mouse | <i>in vivo</i> γδ T cell depletion, FC | UC3-10A6 | BE0168 | |



For over 20 years, scientists have trusted Bio X Cell as their go-to source for *in vivo* functional grade antibodies. This is reflected in over 15,000 peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.

Bio X Cell, Inc.
bxcell.com | 1.866.787.3444
customerservice@bxcell.com

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.
Bio X Cell, Bio X Cell Logo and all other trademarks are the property of Bio X Cell, Inc. © 2020 Bio X Cell

